Peanut Allergy: Opportunity Analysis and Forecasts to 2027
Summary
Peanut allergy is defined as a harmful health effect resulting from a specific and reproducible immune response following the ingestion of peanuts. While exposure to dietary antigens within the gastrointestinal tract normally leads to oral tolerance, in certain individuals this mechanism fails. This results in sensitization and subsequent allergic responses towards innocuous food antigens. The most dangerous of these responses is an acute systemic reaction called anaphylaxis.
Peanut allergy has prevalence of 12.5% in developed nations and a low rate of remissiononly around 20% in children. Though the specific etiology of peanut allergy is unclear, it is likely due to the interaction of genetic predisposition with environmental factors . Currently the only available strategy for managing peanut allergy longterm is avoidance and the treatment of acute reactions with injectable epinephrine. Some physicians have begun to offer their patients an investigational treatment known as experimental peanut oral immunotherapy. Though these grassroots efforts can be effective in desensitizing patients to peanut, they lack standardization and regulatory agency approval, thus making it difficult to ensure the safety of the treatment. With a complete absence of approved therapies available, peanut allergy is an indication with extremely high unmet need.
GlobalData projects the global peanut allergy marketplace which, for the purposes of this report, comprises eight major pharmaceutical markets US, France, Germany, Italy, Spain, UK, Canada, and Australia to experience intense growth during the forecast period. GlobalData forecasts the peanut allergy market to grow over 1,700fold between 2017 and 2027. This incredible growth stems from the projected entry of four new peanut immunotherapy products into a previously empty marketplace. These new therapies include three oral immunotherapy OIT productsAimmune Therapeutics' AR101, Prota Therapeutics' PPOIT, and Camallergy's CA002and one epicutaneous immunotherapy productDBV Technologies' Viaskin Peanut.
Growing at a compound annual growth rate CAGR of 111% over the 10year forecast period, in 2027 peanut allergy sales are projected to reach over $4.5 billion. The majority of sales 88% will come from the US. This is mainly due to the US having a large population of potential patients estimated 3,000,000 probable diagnosed prevalent cases, an elevated expected price tag for new therapies nearly 57 times that of the other geographies, and a higher expected treatment rate based on good accessibility to allergy specialists.
Aimmune's AR101, is expected to be the market leader among the four peanut immunotherapy products released during the forecast, period, capturing over 67% of the peanut allergy market in 2027, worth an estimated $3.0B. Second in sales is DBV Technologies' Viaskin Peanut, which is projected to capture 32% of the peanut allergy market in 2027, totaling nearly $1.4B in sales. Finally, sales for Prota Therapeutics' and Camallergy's products, PPOIT and CA002, together are only expected to total 1%. This estimate is based on GlobalData's assumption that within the forecast period these therapies will each only be released in one geographyAustralia and the 5EU respectively.
Key Questions Answered
The projected entry of four new peanut immunotherapy products during the forecast period is expected to spur intense growth within the peanut allergy market. How are these immunotherapy products similar and different? What are the strengths and weaknesses of the small biotech and startup companies launching these therapies? Which of these drugs will have the highest peak sales, and why?
Key Opinion Leaders KOLs interviewed by GlobalData have indicated that there are considerably high unmet needs within the peanut allergy indication. What are the main unmet needs in this market? How can the pharmaceutical industry address these needs? To what degree will the therapies under development fulfill these unmet needs?
The peanut allergy market is likely to remain a dynamic, growing space throughout the forecast period and beyond. What are the main RD trends in this market and which companies are leading the way? Are there major differences in the mechanisms of action used by therapies in latestage versus early stage clinical development?
Scope
Overview of peanut allergy including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized peanut allergy therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2017 and forecast for ten years to 2027.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the peanut allergy therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of latestage pipeline drugs.
Analysis of the current and future market competition in the global peanut allergy therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to
Develop and design your inlicensing and outlicensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global peanut allergy therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global peanut allergy therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
Track drug sales in the global peanut allergy therapeutics market from 20172027.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.